Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMRT radiochemotherapy plus cetuximab for unresectable head and neck carcinoma
2007-004603-35Phase 2Terminated
- Sponsor
- Heidelberg University
- Start
- Jan 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in oropharyngeal squamous cell carcinoma (OPSCC), squamous cell carcinoma of the hypopharynx, laryngeal squamous cell carcinoma (LSCC) and 1 more, sponsored by Heidelberg University. Primary endpoint: Local-Regional Control. Started Jan 2009; status: terminated.
02
Drugs
cetuximab
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)squamous cell carcinoma of the hypopharynxlaryngeal squamous cell carcinoma (LSCC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2007-004603-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004603-35.